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Abstract
Objective To assess the effect of tranexamic acid on blood transfusion,
thromboembolic events, and mortality in surgical patients.
Design Systematic review and meta-analysis.
Data sources Cochrane central register of controlled trials, Medline,
and Embase, from inception to September 2011, the World Health
Organization International Clinical Trials Registry Platform, and the
reference lists of relevant articles.
Study selection Randomised controlled trials comparing tranexamic
acid with no tranexamic acid or placebo in surgical patients. Outcome
measures of interest were the number of patients receiving a blood
transfusion; the number of patients with a thromboembolic event
(myocardial infarction, stroke, deep vein thrombosis, and pulmonary
embolism); and the number of deaths. Trials were included irrespective
of language or publication status.
Results 129 trials, totalling 10 488 patients, carried out between 1972
and 2011 were included. Tranexamic acid reduced the probability of
receiving a blood transfusion by a third (risk ratio 0.62, 95% confidence
interval 0.58 to 0.65; P<0.001). This effect remained when the analysis
was restricted to trials using adequate allocation concealment (0.68,
0.62 to 0.74; P<0.001). The effect of tranexamic acid on myocardial
infarction (0.68, 0.43 to 1.09; P=0.11), stroke (1.14, 0.65 to 2.00; P=0.65),
deep vein thrombosis (0.86, 0.53 to 1.39; P=0.54), and pulmonary
embolism (0.61, 0.25 to 1.47; P=0.27) was uncertain. Fewer deaths
occurred in the tranexamic acid group (0.61, 0.38 to 0.98; P=0.04),
although when the analysis was restricted to trials using adequate
concealment there was considerable uncertainty (0.67, 0.33 to 1.34;
P=0.25). Cumulative meta-analysis showed that reliable evidence that
tranexamic acid reduces the need for transfusion has been available for
over 10 years.
Conclusions Strong evidence that tranexamic acid reduces blood
transfusion in surgery has been available for many years. Further trials
on the effect of tranexamic acid on blood transfusion are unlikely to add
useful new information. However, the effect of tranexamic acid on
thromboembolic events and mortality remains uncertain. Surgical patients
should be made aware of this evidence so that they can make an
informed choice.
Introduction
In October 2011 the BMJ published a randomised controlled
trial on the effect of tranexamic acid on blood transfusion in
patients undergoing radical retropubic prostatectomy.
1 The
authorspointedoutthatthiswasthefirsttrialtoassesstheeffect
of tranexamic acid on blood transfusion in this particular
operation. While this may be the case, it was not the first trial
to examine the effect of tranexamic acid on blood transfusion
in surgery more generally. A systematic review published in
2001 presented data from 18 clinical trials and showed that
tranexamic acid reduces the probability of blood transfusion in
elective surgery by 34%.
2
We assessed the current evidence for the effect of tranexamic
acidonbloodtransfusion,thromboembolicevents,andmortality
in surgical patients. To examine how the evidence has changed
over time we used cumulative meta-analyses.
Methods
Although we specified and documented the methods of the
analysis and inclusion criteria for this systematic review in
advance, the protocol was not registered. We searched for all
randomisedcontrolledtrialsthatcomparedtranexamicacidwith
no tranexamic acid or placebo in elective and emergency
surgery. No age restriction was applied. Potentially eligible
trialswereidentifiedbysearchingtheCochranecentralregister
ofcontrolledtrials(2011,issue3),Medline(1950toSeptember
2011), and Embase (1980 to September 2011), using a
combination of subject headings and text words to identify
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Forest plots of effects of tranexamic acid in surgery on risk of blood transfusion, thromboembolic events, and mortality
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Research
RESEARCHrandomised controlled trials of any antifibrinolytic drug (see
supplementary file for Medline search strategy). Searches were
not restricted by language or publication status. To identify
ongoing or unpublished trials we searched the WHO
International Clinical Trials Registry Platform. We also
examined the reference lists of eligible trials and reviews. Two
authors independently screened the search output to identify
recordsofpotentiallyeligibletrials,thefulltextsofwhichwere
retrieved and assessed for inclusion.
Outcome data
Outcome measures of interest were the number of patients
receiving a blood transfusion; the number of patients with a
thromboembolicevent(myocardialinfarction,stroke,deepvein
thrombosis, and pulmonary embolism); and the number of
deaths.Wecontactedtrialauthorstoobtainanymissingoutcome
data.
Data extraction and risk of bias assessment
We extracted data on the age and sex of trial participants, type
of surgery, dose and timing of tranexamic acid, type of
comparator, and outcome data. We also collected information
on whether a systematic review had been conducted to support
the trial rationale and whether a systematic review was cited in
the trial report. We assessed the risk of bias associated with the
method of sequence generation, allocation concealment,
blinding, and the completeness of outcome data. As the risk of
bias for blinding may vary according to outcome, we assessed
this separately for each outcome. We rated the risk of bias as
being low, unclear, or high according to established criteria.
3
Statistical analysis
Foreachoutcomewecalculatedriskratiosand95%confidence
intervals.Wepooledtheseusingafixedeffectmodel.Subgroup
analyses were carried out to examine whether the effect of
tranexamic acid on blood transfusion varied by type of surgery.
Sensitivity analyses were done to quantify the effect of
tranexamic acid on all outcomes when restricted to trials with
adequate allocation concealment and blinded outcome
assessment. We carried out a cumulative meta-analysis of the
effectoftranexamicacidonbloodtransfusionbasedonthedate
of publication, and, when restricted to trials with adequate
concealment, cumulative meta-analyses of the effect of
tranexamic acid on blood transfusion, myocardial infarction,
andmortality.Heterogeneitywasexaminedbyvisualinspection
of forest plots, the I
2 statistic, and the χ
2 test. We inspected
funnel plots for the presence of small study effects. Statistical
analyses were carried out using Stata version 11 and RevMan
version 5.
4 5
Results
Overall,127articles
1 6-131describing129randomisedcontrolled
trialsandtotalling10488patientswereincluded;5484ofthese
patientswereallocatedtotranexamicacidand5004toacontrol
group (fig 1⇓). The median sample size was 60 (range 10-660)
patients. In total, 126 (98%) trials were in elective surgery and
three (2%) in emergency surgery. Eleven (8%) trials involved
children.
The authors of 86 trials were contacted for missing data, 39 of
whom provided additional information. Data were available on
bloodtransfusionfrom95(74%)trials,onmyocardialinfarction
from 73 (56%), on stroke from 71 (55%), on deep vein
thrombosis from 72 (56%), on pulmonary embolism from 66
(51%), and on mortality from 72 (56%). Seven (5%) trials did
not present any data on the outcome measures of interest to this
review or reported data in a format that was unsuitable for
inclusion in the analyses.
A further 14 ongoing trials were identified,
132-145 with a median
planned sample size of 130 patients. The 14 trials were in
orthopaedic (n=5), cardiac (n=4), cranial (n=2), hepatic (n=1),
ear, nose, and throat (n=1), and gynaecological (n=1) surgery.
In 12 of the 14 trials blood transfusion was a main outcome
measure.
Risk of bias
Overall, 44 (34%) trials were judged to be at low risk of bias
for sequence generation and five (4%) to be at high risk (see
the supplementary file for the risk of bias judgments for each
methodological quality item for the included trials). The risk of
bias in the remaining 80 (62%) trials was unclear owing to lack
ofinformation.Allocationwasadequatelyconcealedin36trials
(28%) and inadequately concealed in six (5%), with the other
87(67%)presentinginsufficientinformationtoallowjudgment.
Of the 95 trials with data on blood transfusion, 69 (73%) were
judged at low risk of blinding, four (4%) at high risk, and 22
(23%) were unclear. The risk of bias for blinding was similar
for thromboembolic outcomes (myocardial infarction, stroke,
deep vein thrombosis, and pulmonary embolism), with about
70% judged to be at low risk, 5% at high risk, and 25% at
unclear risk. All 72 trials with mortality outcomes were judged
to be at low risk of bias for blinding. Of 115 trials reporting
eligible outcome data, 72 (63%) were at low risk of bias for
incomplete outcome data, 17 (15%) at high risk, and 26 (23%)
did not describe adequate information to permit judgment.
Quantitative data synthesis
Table 1⇓ presents the results of the meta-analysis.
Risk of blood transfusion
Dataonbloodtransfusionwereavailablefor95trials,including
atotalof7838patients.Tranexamicacidreducedtheprobability
of receivingabloodtransfusionby38% (pooled riskratio 0.62,
95% confidence interval 0.58 to 0.65; P<0.001). When the
analysis was restricted to the 32 adequately concealed trials
involving 3408 patients, tranexamic acid reduced the risk of
receiving a blood transfusion by 32% (0.68, 0.62 to 0.74;
P<0.001). When the analysis was restricted to the 69 trials
involving5968patientswithadequateblindingforthisoutcome,
tranexamic acid reduced the risk of blood transfusion by 37%
(0.63, 0.59 to 0.68; P<0.001).
The trials with blood transfusion data involved cardiac (n=42),
orthopaedic (n=36), cranial and orthognathic (n=7),
gynaecological (n=5), hepatic (n=2), urological (n=2), and
vascular (n=1) surgery. Blood transfusion was statistically
significantly reduced in cardiac, orthopaedic, cranial and
orthognathic, hepatic, and urological surgery (table 2⇓). The
pooled estimates for blood transfusion were consistent with a
reduction in the tranexamic acid group among trials in vascular
andgynaecologicalsurgery,althoughtheresultswereimprecise.
There was moderate heterogeneity in magnitude of the effects
of tranexamic acid by type of surgery, although the direction of
the effects was largely consistent.
Thromboembolic events
There was uncertainty about the effect of tranexamic acid on
myocardial infarction (risk ratio 0.68, 95% confidence interval
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RESEARCH0.43 to 1.09; P=0.11), stroke (1.14, 0.65 to 2.00; P=0.65), deep
vein thrombosis (0.86, 0.53 to 1.39; P=0.54), and pulmonary
embolism(0.61,0.25to1.47;P=0.27).Theresultsweresimilar
when the analyses were restricted to trials with adequate
allocation concealment and those with blinded outcome
assessment.
Mortality
Fewer deaths occurred in the tranexamic acid group (risk ratio
0.61, 95% confidence interval 0.38 to 0.98; P=0.04), although
there was uncertainty about this effect, particularly when the
analysiswasrestrictedtothe28trialswithadequateconcealment
(0.67, 0.33 to 1.34; P=0.25).
Cumulative meta-analyses
The supplementary file shows the results of the cumulative
meta-analysis of the 95 trials with data on blood transfusion. A
statistically significant effect of tranexamic acid on blood
transfusion was first observed after publication of the third trial
in 1993 (0.59, 0.43 to 0.80; P=0.001). Although subsequent
trials have increased the precision of the point estimate, no
substantive change has occurred in the direction or magnitude
of the treatment effect.
Figures 2-4⇓⇓⇓ shows the cumulative meta-analyses of the
effect of tranexamic acid on blood transfusion, myocardial
infarction, and mortality among the trials with adequate
allocation concealment. A statistically significant effect of
tranexamicacidonbloodtransfusionwasconsistentlyobserved
after publication of the 10th trial in 2001.
Small study effects
Inspection of the funnel plot (fig 5⇓) for the outcome blood
transfusion suggested the presence of small study effects
favouringtranexamicacid.Theotheroutcomesshowednoclear
asymmetry in the funnel plots.
Citation of previous systematic reviews
Between 1994 and 2011, 30 systematic reviews have been
published on the effects of tranexamic acid in surgery.
2 89 146-175
Assuminga12monthpublicationtimelag,98ofthe116(84%)
included trial reports published as full journal articles were
published when at least one systematic review was available.
Examinationofthereferencelistsofthesereportsindicatedthat
45 (46%) did not cite any of the available systematic reviews.
The authors of two of the 116 trial reports had carried out a
systematic review and presented the findings within the final
trial publication.
Discussion
Reliableevidencethattranexamicacidreducesbloodtransfusion
in surgical patients has been available for many years. The
treatment effect varies somewhat according to the type of
surgery,buttheeffectisconsistentlylargeandremainssowhen
the analysis is restricted to trials with adequate allocation
concealment.Theeffectoftranexamicacidonthromboembolic
eventsandmortalityhasnotbeenadequatelyassessedbyclinical
trialsinsurgeryandremainsuncertain.Inviewoftheevidence,
those planning further placebo controlled trials should explain
why they think that tranexamic acid might not reduce the risk
of blood transfusion in the particular group of surgical patients
under consideration and focus their efforts on resolving the
uncertainties about the effect of tranexamic acid on
thromboembolic events and mortality.
Strengths and weaknesses of the review
Theinferencesthatcanbemadefromtheincludedtrialsdepend
on their quality, and many had methodological limitations.
However, the large and statistically significant effect on blood
transfusion remained when the analysis was restricted to trials
with adequate allocation concealment and with adequate
blinding.
We systematically searched a range of databases for published
and unpublished trials. However, we cannot exclude the
possibility that some were missed. Indeed, the observed
asymmetry in the funnel plot could be explained by publication
bias. If many unpublished trials show little or no effect of
tranexamic acid on blood transfusion, then this meta-analysis
may have overestimated the treatment effect. Although some
degree of overestimation is likely, it seems improbable that
publication bias could account for all of the observed effect.
Although mortality and thromboembolic outcomes showed no
obvious asymmetry in the funnel plots, publication and other
reporting biases remain a potential threat to the validity of the
effect estimates. Mortality data were reported in only a third of
theincludedtrials,andlessthanhalfreporteddataonmyocardial
infarction, stroke, deep vein thrombosis, and pulmonary
embolism.Inadequatereportingofadverseeventsisnotunusual
in reports of clinical trials and hinders the reliable estimation
of treatment effects.
176 177 After contacting the trial authors we
obtained some missing data and were able to include mortality
data for three quarters of the included trials and data on
myocardial infarction, stroke, deep vein thrombosis, and
pulmonary embolism for about half of the trials. However, the
effect of outcome reporting bias in this review remains open to
question. Even if there was no significant bias, the precision of
the estimates is low and the data are compatible with either a
moderate increase or a moderate decrease in the risk of
thromboembolic events.
Implications of the findings
The evidence in this review suggests that the uncertainty about
the effect of tranexamic acid on blood transfusion in surgical
patientswasresolvedoveradecadeago;however,uncertainties
aboutitseffectonthromboemboliceventsandmortalitypersist.
Despite this, trials of tranexamic acid continue to assess the
effect on blood transfusion. One reason may be a reluctance to
generalise the evidence across surgery types, although there is
no evidence that the relative effect of tranexamic acid on blood
transfusion varies by type of surgery. A second reason may be
thattrialistsareunawareoftheexistingevidencewheninitiating
a new trial. Our observation that only half of the trials cited one
ormoreoftheavailablesystematicreviewsandjusttwocarried
outtheirownsystematicreview,doessuggestthatmanytrialists
are indeed failing to adequately consider the existing evidence.
Blood is a scarce and costly resource and blood transfusion is
not without risk. The cost of a unit of red cells to the National
Health Service has increased from £78 (€96; $126) in 2000 to
£125in2011,andbloodtransfusionhasseveralrarebutserious
adverse effects. Worldwide, most people do not have access to
safeblood.Globallythemostimportanttransfusionrelatedrisks
are HIV, hepatitis B virus, and hepatitis C virus, due to their
high prevalence. That tranexamic acid safely reduces the need
for blood transfusion in surgery has important health and
economic implications in high, middle, and low income
countries. The evidence that tranexamic acid reduces the need
for blood transfusion is strong but the safety of routine use of
tranexamicacidinsurgicalpatientsremainsuncertain.Amodest
increase in the risk of thromboembolic effects could outweigh
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RESEARCHthebenefitsofreducedblooduse.Althoughsomeincreasedrisk
mightbeexpectedontheoreticalgrounds,recentevidencefrom
the CRASH-2 (Clinical Randomisation of an Antifibrinolytic
inSignificantHaemorrhage)trialoftranexamicacidinbleeding
trauma patients showed a statistically significant reduction in
mortality with no increase in thromboembolic effects. Indeed,
there was a statistically significant reduction in the risk of
myocardial infarction in trauma patients who received
tranexamic acid.
178
Further small trials of tranexamic acid in surgical patients
considered in isolation will not resolve the uncertainties about
the effects on thromboembolic events and mortality. Because
thromboembolic events are relatively rare, such trials lack
statistical power to detect clinically important increases in risk,
and a meta-analysis of small trials remains vulnerable to
publication bias. The ongoing Aspirin and Tranexamic Acid
for Coronary Artery Surgery trial
179 with a planned sample size
of 4300 high risk patients undergoing coronary artery surgery,
shouldcontributeimportantlytoresolvingtheuncertaintyabout
the effect of tranexamic acid on mortality and thromboembolic
events in this specific group. We urge investigators involved in
all ongoing trials of tranexamic acid in surgery to collect data
on thromboembolic events and mortality for inclusion in a
prospective meta-analysis until the uncertainties are resolved.
However, a need remains for a large pragmatic clinical trial of
the effect of routine use of tranexamic acid in a heterogeneous
group of surgical patients. The possibility that tranexamic acid
might reduce mortality without any increase in the risk of
thromboemboliceventswouldjustifytheeffortandexpenditure
involved.
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RESEARCHWhat is already known on this topic
Small trials on the effect of tranexamic acid (TXA) on blood transfusion in surgical patients continue to be carried out and published in
the medical literature
What this study adds
Evidence that TXA reduces blood transfusion in surgical patients has been available for over a decade, yet the effect on thromboembolic
events and mortality remains uncertain
Further trials on the effect of TXA on blood transfusion are unlikely to add useful new information
A large pragmatic clinical trial of TXA in a heterogeneous group of surgical patients is needed to resolve the uncertainties about the
effects on thromboembolic events and mortality
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RESEARCHTables
Table 1| Meta-analysis of effect of tranexamic acid on blood transfusion, thromboembolic events, and mortality
Heterogeneity
P value* Pooled risk ratio (95% CI) Events (tranexamic acid/control) Outcomes P value I
2 (%)
Blood transfusion:
<0.001 69 <0.001 0.62 (0.58 to 0.65) 1067/1520 All trials
<0.001 55 <0.001 0.68 (0.62 to 0.74) 459/ 609 Well concealed trials
<0.001 54 <0.001 0.63 (0.59 to 0.68) 847/1182 Adequate blinding
Myocardial infarction:
0.90 0 0.11 0.68 (0.42 to 1.09) 23/35 All trials
0.82 0 0.22 0.70 (0.39 to 1.25) 16/25 Well concealed trials
0.81 0 0.04 0.59 (0.36 to 0.98) 18/33 Adequate blinding
Stroke:
0.92 0 0.65 1.14 (0.65 to 2.00) 23/16 All trials
0.92 0 0.78 1.18 (0.36 to 3.83) 5/4 Well concealed trials
0.92 0 0.65 1.14 (0.65 to 2.00) 23/16 Adequate blinding
Deep vein thrombosis:
0.96 0 0.54 0.86 (0.53 to 1.39) 25/29 All trials
0.81 0 0.81 0.92 (0.45 to 1.85) 13/14 Well concealed trials
0.98 0 0.49 0.82 (0.46 to 1.44) 18/22 Adequate blinding
Pulmonary embolism:
0.96 0 0.27 0.61 (0.25 to 1.47) 4/8 All trials
0.80 0 0.44 0.52 (0.10 to 2.75) 1/3 Well concealed trials
0.91 0 0.48 0.70 (0.26 to 1.87) 4/6 Adequate blinding
Mortality:
0.97 0 0.04 0.61 (0.38 to 0.98) 20/34 All trials
0.85 0 0.25 0.67 (0.33 to 1.34) 9/15 Well concealed trials
0.97 0 0.04 0.61 (0.38 to 0.98) 20/34 Adequate blinding
*Test for effect.
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RESEARCHTable 2| Meta-analysis of effect of tranexamic acid on risk of blood transfusion, stratified by type of surgery
Heterogeneity P value* Pooled risk ratio (95% CI) No of events (tranexamic acid/control) Type of surgery
<0.001 60 <0.001 0.65 (0.60 to 0.70) 622/835 Cardiac
<0.001 83 <0.001 0.55 (0.49 to 0.61) 298/462 Orthopaedic
<0.001 93 <0.001 0.52 (0.39 to 0.68) 29/54 Hepatic
0.31 2 0.01 0.66 (0.48 to 0.91) 40/60 Urological
— — 0.05 0.58 (0.34 to 0.99) 11/19 Vascular
0.06 65 0.61 0.86 (0.48 to 1.54) 17/50 Gynaecological
0.12 46 0.004 0.63 (0.45 to 0.86) 52/76 Cranial and orthognathic
*Test for effect.
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RESEARCHFigures
Fig 1 Selection of trials for review
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RESEARCHFig 2 Cumulative meta-analysis of the effect of tranexamic acid in surgery on risk of blood transfusion in adequately
concealed trials
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RESEARCHFig 3 Cumulative meta-analysis of the effect of tranexamic acid in surgery on risk of myocardial infarction in adequately
concealed trials
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RESEARCHFig 4 Cumulative meta-analysis of the effect of tranexamic acid in surgery on risk of death in adequately concealed trials
Fig 5 Funnel plot with pseudo 95% confidence limits for meta-analysis on effect of tranexamic acid on risk of blood transfusion
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